Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations

Patients with hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infectio...

Full description

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 41; no. 1; pp. 3 - 15
Main Authors Passamonti, Francesco, Nicastri, Emanuele, Di Rocco, Alice, Guarini, Attilio, Ibatici, Adalberto, Luminari, Stefano, Mikulska, Malgorzata, Visco, Carlo
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.02.2023
John Wiley and Sons Inc
Subjects
Antibodies, Monoclonal
Antiretroviral drugs
antiviral
Antiviral agents
Antiviral Agents - therapeutic use
Antiviral drugs
Blood cancer
Comorbidity
Coronaviruses
COVID-19
COVID-19 Vaccines
Health services
Humans
Immune response
Immune system
Immunization
Immunization (passive)
immunosuppression
Immunosuppressive agents
Infections
Lymphoma
Lymphoma - drug therapy
Malignancy
Monoclonal antibodies
monoclonal antibody
Narratives
Pandemics
Patients
Prophylaxis
Respiratory diseases
Review
Ritonavir
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Viral diseases
COVID-19
immunosuppression
SARS-CoV-2
monoclonal antibody
antiviral
lymphoma
Online AccessGet full text
ISSN0278-0232
1099-1069
1099-1069
DOI10.1002/hon.3086

Cover

Abstract Patients with hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID‐19) compared to the general population. Although COVID‐19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID‐19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS‐CoV‐2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir‐boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID‐19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID‐19. Our ultimate goal is to provide practice‐oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow‐up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID‐19; the outcomes of COVID‐19 vaccination will also be addressed. We will then discuss current COVID‐19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID‐19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.
AbstractList Patients with hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID‐19) compared to the general population. Although COVID‐19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID‐19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS‐CoV‐2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir‐boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID‐19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID‐19. Our ultimate goal is to provide practice‐oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow‐up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID‐19; the outcomes of COVID‐19 vaccination will also be addressed. We will then discuss current COVID‐19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID‐19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.
Patients with hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID‐19) compared to the general population. Although COVID‐19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID‐19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS‐CoV‐2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir‐boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID‐19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID‐19. Our ultimate goal is to provide practice‐oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow‐up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID‐19; the outcomes of COVID‐19 vaccination will also be addressed. We will then discuss current COVID‐19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID‐19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.
Patients with hematologic malignancies can be immunocompromized because of their disease, anti-cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID-19) compared to the general population. Although COVID-19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID-19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS-CoV-2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir-boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID-19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID-19. Our ultimate goal is to provide practice-oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow-up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID-19; the outcomes of COVID-19 vaccination will also be addressed. We will then discuss current COVID-19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID-19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.Patients with hematologic malignancies can be immunocompromized because of their disease, anti-cancer therapy, and concomitant immunosuppressive treatment. Furthermore, these patients are usually older than 60 years and have comorbidities. For all these reasons they are highly vulnerable to infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and have an increased risk of developing severe/critical Coronavirus disease 2019 (COVID-19) compared to the general population. Although COVID-19 vaccination has proven effective in reducing the incidence of severe/critical disease, vaccinated patients with lymphoma may not be protected as they often fail to develop a sufficient antiviral immune response. There is therefore an urgent need to address the management of patients with lymphoma and COVID-19 in the setting of the ongoing pandemic. Passive immunization with monoclonal antibodies against SARS-CoV-2 is a currently available complementary drug strategy to active vaccination for lymphoma patients, while monoclonal antibodies and antiviral drugs (remdesivir, ritonavir-boosted nirmatrelvir, and molnupiravir) have proven effective in preventing the progression to severe/critical COVID-19. In this narrative review we present the most recent data documenting the characteristics and outcomes of patients with concomitant lymphoma and COVID-19. Our ultimate goal is to provide practice-oriented guidance in the management of these vulnerable patients from diagnosis to treatment and follow-up of lymphoma. To this purpose, we will first provide an overview of the main data concerning prognostic factors and fatality rate of lymphoma patients who develop COVID-19; the outcomes of COVID-19 vaccination will also be addressed. We will then discuss current COVID-19 prophylaxis and treatment options for lymphoma patients. Finally, based on the literature and our multidisciplinary experience, we will summarize a set of indications on how to manage patients with lymphoma according to COVID-19 exposure, level of disease severity and former history of infection, as typically encountered in clinical practice.
Author Di Rocco, Alice
Mikulska, Malgorzata
Guarini, Attilio
Luminari, Stefano
Ibatici, Adalberto
Nicastri, Emanuele
Visco, Carlo
Passamonti, Francesco
AuthorAffiliation 3 National Institute of Infectious Diseases “L. Spallanzani” IRCCS Roma Italy
11 Department of Medicine Section of Hematology University of Verona Verona Italy
2 Hematology, ASST Sette Laghi, Ospedale di Circolo Varese Italy
10 Division of Infectious Diseases Department of Health Sciences (DISSAL) University of Genova Genova Italy
5 Hematology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy
9 IRCCS Ospedale Policlinico San Martino Genova Italy
8 Dipartimento CHIMOMO Università di Modena e Reggio Emilia Reggio Emilia Italy
1 Department of Medicine and Surgery University of Insubria Varese Italy
4 Department of Cellular Biotechnologies and Hematology Hematology Unit Sapienza University Roma Italy
6 Hematology Unit and Bone Marrow Transplantation IRCCS Ospedale Policlinico San Martino Genova Italy
7 Hematology Unit Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia Reggio Emilia Italy
AuthorAffiliation_xml – name: 7 Hematology Unit Azienda Unità Sanitaria Locale, IRCCS Reggio Emilia Reggio Emilia Italy
– name: 8 Dipartimento CHIMOMO Università di Modena e Reggio Emilia Reggio Emilia Italy
– name: 2 Hematology, ASST Sette Laghi, Ospedale di Circolo Varese Italy
– name: 5 Hematology Unit IRCCS Istituto Tumori “Giovanni Paolo II” Bari Italy
– name: 9 IRCCS Ospedale Policlinico San Martino Genova Italy
– name: 1 Department of Medicine and Surgery University of Insubria Varese Italy
– name: 3 National Institute of Infectious Diseases “L. Spallanzani” IRCCS Roma Italy
– name: 10 Division of Infectious Diseases Department of Health Sciences (DISSAL) University of Genova Genova Italy
– name: 11 Department of Medicine Section of Hematology University of Verona Verona Italy
– name: 4 Department of Cellular Biotechnologies and Hematology Hematology Unit Sapienza University Roma Italy
– name: 6 Hematology Unit and Bone Marrow Transplantation IRCCS Ospedale Policlinico San Martino Genova Italy
Author_xml – sequence: 1
  givenname: Francesco
  orcidid: 0000-0001-8068-5289
  surname: Passamonti
  fullname: Passamonti, Francesco
  email: francesco.passamonti@uninsubria.it
  organization: Hematology, ASST Sette Laghi, Ospedale di Circolo
– sequence: 2
  givenname: Emanuele
  surname: Nicastri
  fullname: Nicastri, Emanuele
  organization: IRCCS
– sequence: 3
  givenname: Alice
  surname: Di Rocco
  fullname: Di Rocco, Alice
  organization: Sapienza University
– sequence: 4
  givenname: Attilio
  surname: Guarini
  fullname: Guarini, Attilio
  organization: IRCCS Istituto Tumori “Giovanni Paolo II”
– sequence: 5
  givenname: Adalberto
  surname: Ibatici
  fullname: Ibatici, Adalberto
  organization: IRCCS Ospedale Policlinico San Martino
– sequence: 6
  givenname: Stefano
  surname: Luminari
  fullname: Luminari, Stefano
  organization: Università di Modena e Reggio Emilia
– sequence: 7
  givenname: Malgorzata
  surname: Mikulska
  fullname: Mikulska, Malgorzata
  organization: University of Genova
– sequence: 8
  givenname: Carlo
  surname: Visco
  fullname: Visco, Carlo
  organization: University of Verona
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36251481$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1uEzEUhS3UiqYFiSdAltiwmdR_M_awQEJpoZVKswG2lsdjN65m7MGeJMquj9Bn5Elwkrb8CCRLvtL97vG5PsfgwAdvAHiF0RQjRE4XwU8pEtUzMMGorguMqvoATBDhokCEkiNwnNItQrmHxHNwRCtSYibwBIyflVc3pjd-hMHCQY0ulwmu3biA3aYfFqFXUPkWzubfLs9-3N3j-h28VjFmcmVgNCtn1jsgV63x2mSmUcm0cIhKj06rLlM69PmNNg8Fn16AQ6u6ZF4-3Cfg68fzL7OL4mr-6XL24arQjIqqqGuLGdWstdgy1dhai4pSy1siaGPzsajMIOeCGdLYsimp4hUuq5YrihmnJ-D9XndYNr1pdd4sqk4O0fUqbmRQTv7Z8W4hb8JK1oKzUuAs8PZBIIbvS5NG2bukTdcpb8IyScJJyRgWVGT0zV_obVhGn9fLFMeEUVptHb3-3dGTlcdAMjDdAzqGlKKxUrtx92vZoOskRnKbuMyJy23ivyw-DTxq_gMt9ujadWbzX05ezK93_E-XPry2
CitedBy_id crossref_primary_10_7889_tct_24_006
crossref_primary_10_1002_cam4_6678
crossref_primary_10_1007_s00277_024_06057_4
crossref_primary_10_1111_bjh_19422
crossref_primary_10_1186_s12879_023_08797_6
crossref_primary_10_31718_2077_1096_24_1_168
crossref_primary_10_1155_2024_8182887
crossref_primary_10_1007_s12185_024_03711_5
crossref_primary_10_3389_fcimb_2023_1207225
crossref_primary_10_1002_ijc_35377
crossref_primary_10_1186_s40164_024_00551_1
crossref_primary_10_3390_jcm13185400
crossref_primary_10_2174_0126667975259296240409061101
crossref_primary_10_3390_curroncol31090393
crossref_primary_10_1186_s12879_022_07918_x
crossref_primary_10_3389_fonc_2024_1290614
Cites_doi 10.1016/j.blre.2020.100775
10.1182/blood.2021013445
10.1056/NEJMc2201933
10.1016/S2213‐2600(22)00180‐1
10.1056/NEJMoa2107934
10.1182/blood‐2021‐151419
10.1056/NEJMoa2119657
10.1016/j.esmoop.2021.100274
10.1038/s41586‐020‐2521‐4
10.1182/bloodadvances.2021005691
10.1002/ajh.26322
10.1182/bloodadvances.2021004629
10.5501/wjv.v10.i6.312
10.1056/NEJMoa2034577
10.1182/blood.2020008824
10.1016/j.eclinm.2020.100549
10.3324/haematol.2021.280163
10.1056/NEJMoa2101544
10.1002/ajh.26209
10.1002/ajh.26629
10.1097/HS9.0000000000000538
10.1056/NEJMoa2108163
10.1016/S1470‐2045(20)30442‐3
10.1182/bloodadvances.2021006101
10.1016/S2352‐3026(21)00199‐X
10.1056/NEJMoa2035389
10.1101/2021.06.02.21257804
10.1038/s41375‐020‐0836‐7
10.1016/S0140‐6736(20)31187‐9
10.1038/s41571‐022‐00610‐8
10.3324/haematol.2021.279216
10.3389/fped.2021.629240
10.1111/bjh.17704
10.1056/NEJMoa2035002
10.1186/s13045‐021‐01177‐0
10.1016/S0140‐6736(16)32407‐2
10.1186/s13045‐022‐01233‐3
10.1016/j.ccell.2021.11.006
10.1056/NEJMoa2118542
10.1186/s13045‐020‐00970‐7
10.1016/S1470‐2045(21)00573‐8
10.1016/j.esmoop.2022.100403
10.1016/S2352‐3026(20)30251‐9
10.1056/NEJMoa2029849
10.1016/j.annonc.2021.12.006
10.1016/S2213‐2600(22)00215‐6
10.1038/s41416‐021‐01500‐z
10.1016/j.cmi.2022.06.029
10.1056/NEJMc2119407
10.1126/science.acx9591
10.1016/S2352‐3026(21)00073‐9
10.1016/S0140‐6736(20)32661‐1
10.1056/NEJMoa2116846
10.1002/jmv.26404
10.1056/NEJMoa2116620
10.1182/blood.2021014124
10.1001/jama.2022.2832
10.3389/fimmu.2022.911339
10.1182/bloodadvances.2021005094
10.1016/j.cmi.2022.02.029
10.1016/j.annonc.2021.02.024
10.1016/S0140‐6736(22)00147‐7
10.1016/j.ccell.2022.05.007
10.1111/bjh.16956
10.1016/j.ccell.2021.12.013
10.1016/j.ejca.2022.01.035
10.1016/S1473‐3099(21)00762‐3
10.1056/NEJMoa2116044
10.1016/S1470‐2045(20)30096‐6
ContentType Journal Article
Copyright 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
– notice: 2022. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QO
7QP
7T7
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
DOI 10.1002/hon.3086
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
Genetics Abstracts
Biotechnology Research Abstracts
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts

MEDLINE
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1099-1069
EndPage 15
ExternalDocumentID PMC9874581
36251481
10_1002_hon_3086
HON3086
Genre reviewArticle
Journal Article
Review
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GLUZI
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6P
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
SAMSI
SUPJJ
SV3
TEORI
UB1
UDS
V2E
V8K
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
XG1
XV2
ZGI
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QO
7QP
7T7
7TK
7U9
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
5PM
ID FETCH-LOGICAL-c4386-99f143c4df1f4abf9c8633f7d283bf3bff054387784e2bf5b53a76156d7a31473
IEDL.DBID DR2
ISSN 0278-0232
1099-1069
IngestDate Thu Aug 21 18:38:46 EDT 2025
Fri Jul 11 11:16:21 EDT 2025
Fri Jul 25 21:21:23 EDT 2025
Wed Feb 19 02:25:12 EST 2025
Tue Jul 01 01:30:32 EDT 2025
Thu Apr 24 23:12:30 EDT 2025
Wed Jan 22 16:24:21 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19
immunosuppression
SARS-CoV-2
monoclonal antibody
antiviral
lymphoma
Language English
License Attribution
2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4386-99f143c4df1f4abf9c8633f7d283bf3bff054387784e2bf5b53a76156d7a31473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-8068-5289
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhon.3086
PMID 36251481
PQID 2771243367
PQPubID 2034140
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9874581
proquest_miscellaneous_2725441838
proquest_journals_2771243367
pubmed_primary_36251481
crossref_citationtrail_10_1002_hon_3086
crossref_primary_10_1002_hon_3086
wiley_primary_10_1002_hon_3086_HON3086
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2023
PublicationDateYYYYMMDD 2023-02-01
PublicationDate_xml – month: 02
  year: 2023
  text: February 2023
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
– name: Hoboken
PublicationTitle Hematological oncology
PublicationTitleAlternate Hematol Oncol
PublicationYear 2023
Publisher Wiley Subscription Services, Inc
John Wiley and Sons Inc
Publisher_xml – name: Wiley Subscription Services, Inc
– name: John Wiley and Sons Inc
References 2021; 47
2021; 9
2021; 8
2021; 6
2021; 5
2021; 22
2020; 383
2021; 125
2017; 390
2021; 384
2020; 13
2020; 584
2020; 34
2020; 101
2022; 22
2021; 385
2021; 93
2021; 96
2022; 139
2022; 28
2022; 399
2022; 386
2021; 14
2020; 7
2020; 190
2022; 165
2021; 32
2021; 10
2022
2021
2020; 395
2022; 6
2022; 40
2022; 7
2021; 138
2020; 27
2022; 13
2021; 195
2022; 15
2022; 97
2021; 397
2022; 10
2020; 21
2020; 136
2022; 33
2022; 107
2022; 327
2022; 19
e_1_2_12_4_1
e_1_2_12_6_1
e_1_2_12_19_1
e_1_2_12_2_1
e_1_2_12_38_1
e_1_2_12_20_1
e_1_2_12_41_1
e_1_2_12_66_1
e_1_2_12_87_1
Lewis WD (e_1_2_12_17_1) 2020; 101
e_1_2_12_22_1
e_1_2_12_43_1
e_1_2_12_64_1
e_1_2_12_85_1
e_1_2_12_24_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_47_1
e_1_2_12_68_1
e_1_2_12_89_1
e_1_2_12_62_1
e_1_2_12_83_1
e_1_2_12_60_1
e_1_2_12_81_1
e_1_2_12_28_1
e_1_2_12_49_1
e_1_2_12_31_1
e_1_2_12_52_1
e_1_2_12_77_1
e_1_2_12_33_1
e_1_2_12_54_1
e_1_2_12_75_1
e_1_2_12_35_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_58_1
e_1_2_12_79_1
e_1_2_12_14_1
e_1_2_12_90_1
e_1_2_12_12_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_73_1
e_1_2_12_50_1
e_1_2_12_71_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_5_1
e_1_2_12_18_1
e_1_2_12_16_1
e_1_2_12_39_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_88_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_69_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
e_1_2_12_80_1
e_1_2_12_61_1
e_1_2_12_84_1
e_1_2_12_40_1
e_1_2_12_82_1
e_1_2_12_27_1
e_1_2_12_29_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_78_1
e_1_2_12_15_1
e_1_2_12_91_1
e_1_2_12_13_1
e_1_2_12_11_1
e_1_2_12_72_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_9_1
References_xml – volume: 385
  start-page: 1941
  issue: 21
  year: 2021
  end-page: 1950
  article-title: Early treatment for covid‐19 with SARS‐CoV‐2 neutralizing antibody sotrovimab
  publication-title: N Engl J Med
– volume: 93
  start-page: 1099
  issue: 2
  year: 2021
  end-page: 1104
  article-title: The outcome of COVID‐19 in patients with hematological malignancy
  publication-title: J Med Virol
– volume: 399
  start-page: 905
  issue: 10328
  year: 2022
  end-page: 907
  article-title: Omicron neutralising antibodies after third COVID‐19 vaccine dose in patients with cancer
  publication-title: Lancet
– volume: 397
  start-page: 99
  issue: 10269
  year: 2021
  end-page: 111
  article-title: Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine (AZD1222) against SARS‐CoV‐2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  publication-title: Lancet
– volume: 21
  start-page: 1309
  issue: 10
  year: 2020
  end-page: 1316
  article-title: COVID‐19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
  publication-title: Lancet Oncol
– volume: 386
  start-page: 995
  issue: 10
  year: 2022
  end-page: 998
  article-title: Efficacy of antibodies and antiviral drugs against covid‐19 omicron variant
  publication-title: N Engl J Med
– volume: 190
  start-page: 336
  issue: 3
  year: 2020
  end-page: 345
  article-title: Haematological cancers and the risk of severe COVID‐19: exploration and critical evaluation of the evidence to date
  publication-title: Br J Haematol
– volume: 384
  start-page: 2187
  issue: 23
  year: 2021
  end-page: 2201
  article-title: Safety and efficacy of single‐dose Ad26.COV2.S vaccine against covid‐19
  publication-title: N Engl J Med
– volume: 40
  start-page: 114
  issue: 2
  year: 2022
  end-page: 116
  article-title: Immune responses following third COVID‐19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
  publication-title: Cancer Cell
– volume: 15
  start-page: 15
  issue: 1
  year: 2022
  article-title: Serologic response following SARS‐COV2 vaccination in patients with cancer: a systematic review and meta‐analysis
  publication-title: J Hematol Oncol
– volume: 139
  start-page: 1588
  issue: 10
  year: 2022
  end-page: 1592
  article-title: COVID‐19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
  publication-title: Blood
– volume: 96
  start-page: 934
  issue: 8
  year: 2021
  end-page: 944
  article-title: Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy
  publication-title: Am J Hematol
– volume: 40
  start-page: 590
  issue: 6
  year: 2022
  end-page: 591
  article-title: Activity of AZD7442 (tixagevimab‐cilgavimab) against Omicron SARS‐CoV‐2 in patients with hematologic malignancies
  publication-title: Cancer Cell
– volume: 138
  start-page: 185
  issue: Suppl 1
  year: 2021
  article-title: Sars‐Cov‐2 antibody levels in blood cancer patients after a third sars‐cov‐2 “booster” vaccination – observational data from the LLS national registry
  publication-title: Blood
– volume: 395
  start-page: 1907
  issue: 10241
  year: 2020
  end-page: 1918
  article-title: Clinical impact of COVID‐19 on patients with cancer (CCC19): a cohort study
  publication-title: Lancet
– volume: 21
  start-page: 335
  issue: 3
  year: 2020
  end-page: 337
  article-title: Cancer patients in SARS‐CoV‐2 infection: a nationwide analysis in China
  publication-title: Lancet Oncol
– volume: 19
  start-page: 385
  issue: 6
  year: 2022
  end-page: 401
  article-title: COVID‐19 vaccines in patients with cancer: immunogenicity, efficacy and safety
  publication-title: Nat Rev Clin Oncol
– volume: 384
  start-page: 238
  issue: 3
  year: 2021
  end-page: 251
  article-title: REGN‐COV2, a neutralizing antibody cocktail, in outpatients with covid‐19
  publication-title: N Engl J Med
– volume: 27
  year: 2020
  article-title: Determinants of outcome in Covid‐19 hospitalized patients with lymphoma: a retrospective multicentric cohort study
  publication-title: EClinicalMedicine
– volume: 47
  year: 2021
  article-title: When hematologic malignancies meet COVID‐19 in the United States: infections, death and disparities
  publication-title: Blood Rev
– volume: 6
  start-page: 774
  issue: 3
  year: 2022
  end-page: 784
  article-title: Cellular and humoral immunogenicity of the mRNA‐1273 SARS‐CoV‐2 vaccine in patients with hematologic malignancies
  publication-title: Blood Adv
– volume: 386
  start-page: 2188
  issue: 23
  year: 2022
  end-page: 2200
  article-title: Intramuscular AZD7442 (Tixagevimab‐Cilgavimab) for prevention of covid‐19
  publication-title: N Engl J Med
– volume: 136
  start-page: 2881
  issue: 25
  year: 2020
  end-page: 2892
  article-title: Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients
  publication-title: Blood
– volume: 10
  start-page: 312
  issue: 6
  year: 2021
  end-page: 325
  article-title: COVID‐19 (SARS‐CoV‐2 infection) in lymphoma patients: a review
  publication-title: World J Virol
– volume: 33
  start-page: 340
  issue: 3
  year: 2022
  end-page: 346
  article-title: COVID‐19 vaccination and breakthrough infections in patients with cancer
  publication-title: Ann Oncol
– volume: 6
  start-page: 327
  issue: 1
  year: 2022
  end-page: 338
  article-title: A prognostic model for patients with lymphoma and COVID‐19: a multicentre cohort study
  publication-title: Blood Adv
– volume: 8
  start-page: e542
  issue: 8
  year: 2021
  end-page: e544
  article-title: Antibody responses after SARS‐CoV‐2 vaccination in patients with lymphoma
  publication-title: Lancet Haematol
– volume: 386
  start-page: 1397
  issue: 15
  year: 2022
  end-page: 1408
  article-title: Oral nirmatrelvir for high‐risk, nonhospitalized adults with covid‐19
  publication-title: N Engl J Med
– volume: 385
  start-page: e81
  issue: 23
  year: 2021
  article-title: REGEN‐COV antibody combination and outcomes in outpatients with covid‐19
  publication-title: N Engl J Med
– volume: 40
  start-page: 3
  issue: 1
  year: 2022
  end-page: 5
  article-title: Efficacy of booster doses in augmenting waning immune responses to COVID‐19 vaccine in patients with cancer
  publication-title: Cancer Cell
– volume: 390
  start-page: 298
  issue: 10091
  year: 2017
  end-page: 310
  article-title: Non‐Hodgkin lymphoma
  publication-title: Lancet
– volume: 384
  start-page: 403
  issue: 5
  year: 2021
  end-page: 416
  article-title: Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine
  publication-title: N Engl J Med
– volume: 327
  start-page: 1236
  issue: 13
  year: 2022
  end-page: 1246
  article-title: Effect of sotrovimab on hospitalization or death among high‐risk patients with mild to moderate COVID‐19: a randomized clinical trial
  publication-title: JAMA
– volume: 5
  start-page: 3053
  issue: 16
  year: 2021
  end-page: 3061
  article-title: Efficacy of the BNT162b2 mRNA COVID‐19 vaccine in patients with B‐cell non‐Hodgkin lymphoma
  publication-title: Blood Adv
– volume: 584
  start-page: 430
  issue: 7821
  year: 2020
  end-page: 436
  article-title: Factors associated with COVID‐19‐related death using OpenSAFELY
  publication-title: Nature
– volume: 32
  start-page: 787
  issue: 6
  year: 2021
  end-page: 800
  article-title: Association of clinical factors and recent anticancer therapy with COVID‐19 severity among patients with cancer: a report from the COVID‐19 and Cancer Consortium
  publication-title: Ann Oncol
– volume: 384
  start-page: 229
  issue: 3
  year: 2021
  end-page: 237
  article-title: SARS‐CoV‐2 neutralizing antibody LY‐CoV555 in outpatients with covid‐19
  publication-title: N Engl J Med
– volume: 13
  year: 2022
  article-title: Clinical management of patients with B‐cell depletion agents to treat or prevent prolonged and severe SARS‐COV‐2 infection: defining a treatment pathway
  publication-title: Front Immunol
– volume: 14
  start-page: 168
  issue: 1
  year: 2021
  article-title: COVID‐19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
  publication-title: J Hematol Oncol
– volume: 28
  start-page: 885.e7
  issue: 6
  year: 2022
  end-page: 885.e11
  article-title: Anti‐SARS‐CoV‐2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
  publication-title: Clin Microbiol Infect
– volume: 165
  start-page: 174
  year: 2022
  end-page: 183
  article-title: Survival and risk of COVID‐19 after SARS‐COV‐2 vaccination in a series of 2391 cancer patients
  publication-title: Eur J Cancer
– volume: 386
  start-page: 1700
  issue: 18
  year: 2022
  end-page: 1711
  article-title: Early outpatient treatment for covid‐19 with convalescent plasma
  publication-title: N Engl J Med
– volume: 8
  start-page: e312
  issue: 5
  year: 2021
  end-page: e314
  article-title: COVID‐19 vaccines for patients with haematological conditions
  publication-title: Lancet Haematol
– volume: 22
  start-page: 1669
  issue: 12
  year: 2021
  end-page: 1680
  article-title: Prevalence and impact of COVID‐19 sequelae on treatment and survival of patients with cancer who recovered from SARS‐CoV‐2 infection: evidence from the OnCovid retrospective, multicentre registry study
  publication-title: Lancet Oncol
– volume: 9
  year: 2021
  article-title: COVID‐19 in immunosuppressed children
  publication-title: Front Pediatr
– volume: 107
  start-page: 715
  issue: 3
  year: 2022
  end-page: 720
  article-title: Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti‐CD2O antibodies
  publication-title: Haematologica
– volume: 386
  start-page: 509
  issue: 6
  year: 2022
  end-page: 520
  article-title: Molnupiravir for oral treatment of covid‐19 in nonhospitalized patients
  publication-title: N Engl J Med
– volume: 13
  start-page: 133
  issue: 1
  year: 2020
  article-title: Impact of hematologic malignancy and type of cancer therapy on COVID‐19 severity and mortality: lessons from a large population‐based registry study
  publication-title: J Hematol Oncol
– volume: 6
  issue: 5
  year: 2021
  article-title: Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
  publication-title: ESMO Open
– volume: 34
  start-page: 1637
  issue: 6
  year: 2020
  end-page: 1645
  article-title: COVID‐19 in persons with haematological cancers
  publication-title: Leukemia
– year: 2021
  article-title: Impaired humoral immunity to SARS‐CoV‐2 vaccination in non‐hodgkin lymphoma and CLL patients
  publication-title: medRxiv
– volume: 107
  start-page: 1840
  issue: 8
  year: 2022
  end-page: 1849
  article-title: Antibody response after vaccination against SARS‐CoV‐2 in adults with hematological malignancies: a systematic review and meta‐analysis
  publication-title: Haematologica
– volume: 101
  start-page: 34
  issue: 1
  year: 2020
  end-page: 41
  article-title: Lymphoma: diagnosis and treatment
  publication-title: Am Fam Physician
– volume: 386
  start-page: 1475
  issue: 15
  year: 2022
  end-page: 1477
  article-title: Efficacy of antiviral agents against the SARS‐CoV‐2 omicron subvariant BA.2
  publication-title: N Engl J Med
– volume: 383
  start-page: 2603
  issue: 27
  year: 2020
  end-page: 2615
  article-title: Safety and efficacy of the BNT162b2 mRNA covid‐19 vaccine
  publication-title: N Engl J Med
– volume: 5
  start-page: e538
  issue: 3
  year: 2021
  article-title: Risk factors and mortality of COVID‐19 in patients with lymphoma: a multicenter study
  publication-title: Hemasphere
– volume: 195
  start-page: 371
  issue: 3
  year: 2021
  end-page: 377
  article-title: COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
  publication-title: Br J Haematol
– volume: 22
  start-page: 567
  issue: 5
  year: 2022
  end-page: 569
  article-title: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID‐19
  publication-title: Lancet Infect Dis
– volume: 7
  start-page: e737
  issue: 10
  year: 2020
  end-page: e745
  article-title: Clinical characteristics and risk factors associated with COVID‐19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
  publication-title: Lancet Haematol
– volume: 139
  start-page: 142
  issue: 1
  year: 2022
  end-page: 147
  article-title: Humoral and cellular responses after COVID‐19 vaccination in anti‐CD20‐treated lymphoma patients
  publication-title: Blood
– volume: 10
  start-page: 985
  issue: 10
  year: 2022
  end-page: 996
  article-title: Efficacy and safety of intramuscular administration of tixagevimab‐cilgavimab for early outpatient treatment of COVID‐19 (TACKLE): a phase 3, randomised, double‐blind, placebo‐controlled trial
  publication-title: Lancet Respir Med
– volume: 7
  issue: 2
  year: 2022
  article-title: Managing hematological cancer patients during the COVID‐19 pandemic: an ESMO‐EHA Interdisciplinary Expert Consensus
  publication-title: ESMO Open
– year: 2021
  article-title: A prominent virologist warns COVID‐19 pill could unleash dangerous mutants. Others see little cause for alarm
  publication-title: Science
– volume: 96
  start-page: E410
  issue: 11
  year: 2021
  end-page: E413
  article-title: Serologic response to mRNA COVID‐19 vaccination in lymphoma patients
  publication-title: Am J Hematol
– year: 2022
  article-title: Virological and clinical rebounds of COVID‐19 soon after nirmatrelvir/ritonavir discontinuation
  publication-title: Clin Microbiol Infect
– volume: 125
  start-page: 939
  issue: 7
  year: 2021
  end-page: 947
  article-title: Risk of COVID‐19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London
  publication-title: Br J Cancer
– volume: 10
  start-page: 972
  issue: 10
  year: 2022
  end-page: 984
  article-title: Tixagevimab‐cilgavimab for treatment of patients hospitalised with COVID‐19: a randomised, double‐blind, phase 3 trial
  publication-title: Lancet Respir Med
– volume: 5
  start-page: 2624
  issue: 12
  year: 2021
  end-page: 2643
  article-title: Vaccine response following anti‐CD20 therapy: a systematic review and meta‐analysis of 905 patients
  publication-title: Blood Adv
– volume: 386
  start-page: 305
  issue: 4
  year: 2022
  end-page: 315
  article-title: Early remdesivir to prevent progression to severe covid‐19 in outpatients
  publication-title: N Engl J Med
– volume: 97
  start-page: E321
  issue: 8
  year: 2022
  end-page: E324
  article-title: Immunogenicity and clinical efficacy of anti‐SARS‐CoV‐2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients
  publication-title: Am J Hematol
– ident: e_1_2_12_11_1
  doi: 10.1016/j.blre.2020.100775
– ident: e_1_2_12_54_1
  doi: 10.1182/blood.2021013445
– ident: e_1_2_12_85_1
  doi: 10.1056/NEJMc2201933
– ident: e_1_2_12_91_1
– ident: e_1_2_12_75_1
  doi: 10.1016/S2213‐2600(22)00180‐1
– ident: e_1_2_12_66_1
– ident: e_1_2_12_27_1
  doi: 10.1056/NEJMoa2107934
– ident: e_1_2_12_60_1
  doi: 10.1182/blood‐2021‐151419
– ident: e_1_2_12_64_1
  doi: 10.1056/NEJMoa2119657
– ident: e_1_2_12_49_1
  doi: 10.1016/j.esmoop.2021.100274
– ident: e_1_2_12_3_1
  doi: 10.1038/s41586‐020‐2521‐4
– ident: e_1_2_12_38_1
  doi: 10.1182/bloodadvances.2021005691
– ident: e_1_2_12_51_1
  doi: 10.1002/ajh.26322
– ident: e_1_2_12_48_1
  doi: 10.1182/bloodadvances.2021004629
– ident: e_1_2_12_88_1
– ident: e_1_2_12_39_1
  doi: 10.5501/wjv.v10.i6.312
– ident: e_1_2_12_18_1
  doi: 10.1056/NEJMoa2034577
– ident: e_1_2_12_65_1
– ident: e_1_2_12_15_1
  doi: 10.1182/blood.2020008824
– ident: e_1_2_12_70_1
– ident: e_1_2_12_36_1
  doi: 10.1016/j.eclinm.2020.100549
– ident: e_1_2_12_56_1
  doi: 10.3324/haematol.2021.280163
– ident: e_1_2_12_21_1
  doi: 10.1056/NEJMoa2101544
– ident: e_1_2_12_41_1
  doi: 10.1002/ajh.26209
– ident: e_1_2_12_35_1
  doi: 10.1002/ajh.26629
– ident: e_1_2_12_37_1
  doi: 10.1097/HS9.0000000000000538
– ident: e_1_2_12_69_1
  doi: 10.1056/NEJMoa2108163
– ident: e_1_2_12_13_1
  doi: 10.1016/S1470‐2045(20)30442‐3
– ident: e_1_2_12_57_1
  doi: 10.1182/bloodadvances.2021006101
– ident: e_1_2_12_52_1
  doi: 10.1016/S2352‐3026(21)00199‐X
– ident: e_1_2_12_19_1
  doi: 10.1056/NEJMoa2035389
– ident: e_1_2_12_53_1
  doi: 10.1101/2021.06.02.21257804
– ident: e_1_2_12_5_1
  doi: 10.1038/s41375‐020‐0836‐7
– ident: e_1_2_12_6_1
  doi: 10.1016/S0140‐6736(20)31187‐9
– volume: 101
  start-page: 34
  issue: 1
  year: 2020
  ident: e_1_2_12_17_1
  article-title: Lymphoma: diagnosis and treatment
  publication-title: Am Fam Physician
– ident: e_1_2_12_22_1
  doi: 10.1038/s41571‐022‐00610‐8
– ident: e_1_2_12_24_1
  doi: 10.3324/haematol.2021.279216
– ident: e_1_2_12_14_1
  doi: 10.3389/fped.2021.629240
– ident: e_1_2_12_67_1
– ident: e_1_2_12_43_1
  doi: 10.1111/bjh.17704
– ident: e_1_2_12_29_1
  doi: 10.1056/NEJMoa2035002
– ident: e_1_2_12_83_1
– ident: e_1_2_12_89_1
– ident: e_1_2_12_42_1
  doi: 10.1186/s13045‐021‐01177‐0
– ident: e_1_2_12_16_1
  doi: 10.1016/S0140‐6736(16)32407‐2
– ident: e_1_2_12_78_1
– ident: e_1_2_12_55_1
  doi: 10.1186/s13045‐022‐01233‐3
– ident: e_1_2_12_58_1
  doi: 10.1016/j.ccell.2021.11.006
– ident: e_1_2_12_80_1
– ident: e_1_2_12_63_1
– ident: e_1_2_12_33_1
  doi: 10.1056/NEJMoa2118542
– ident: e_1_2_12_40_1
  doi: 10.1186/s13045‐020‐00970‐7
– ident: e_1_2_12_2_1
– ident: e_1_2_12_47_1
  doi: 10.1016/S1470‐2045(21)00573‐8
– ident: e_1_2_12_77_1
– ident: e_1_2_12_25_1
  doi: 10.1016/j.esmoop.2022.100403
– ident: e_1_2_12_7_1
  doi: 10.1016/S2352‐3026(20)30251‐9
– ident: e_1_2_12_30_1
  doi: 10.1056/NEJMoa2029849
– ident: e_1_2_12_44_1
  doi: 10.1016/j.annonc.2021.12.006
– ident: e_1_2_12_74_1
  doi: 10.1016/S2213‐2600(22)00215‐6
– ident: e_1_2_12_10_1
  doi: 10.1038/s41416‐021‐01500‐z
– ident: e_1_2_12_84_1
  doi: 10.1016/j.cmi.2022.06.029
– ident: e_1_2_12_76_1
  doi: 10.1056/NEJMc2119407
– ident: e_1_2_12_86_1
  doi: 10.1126/science.acx9591
– ident: e_1_2_12_23_1
  doi: 10.1016/S2352‐3026(21)00073‐9
– ident: e_1_2_12_68_1
– ident: e_1_2_12_20_1
  doi: 10.1016/S0140‐6736(20)32661‐1
– ident: e_1_2_12_32_1
  doi: 10.1056/NEJMoa2116846
– ident: e_1_2_12_81_1
– ident: e_1_2_12_8_1
  doi: 10.1002/jmv.26404
– ident: e_1_2_12_31_1
  doi: 10.1056/NEJMoa2116620
– ident: e_1_2_12_46_1
  doi: 10.1182/blood.2021014124
– ident: e_1_2_12_73_1
– ident: e_1_2_12_28_1
  doi: 10.1001/jama.2022.2832
– ident: e_1_2_12_92_1
  doi: 10.3389/fimmu.2022.911339
– ident: e_1_2_12_87_1
– ident: e_1_2_12_79_1
– ident: e_1_2_12_50_1
  doi: 10.1182/bloodadvances.2021005094
– ident: e_1_2_12_61_1
  doi: 10.1016/j.cmi.2022.02.029
– ident: e_1_2_12_9_1
  doi: 10.1016/j.annonc.2021.02.024
– ident: e_1_2_12_62_1
  doi: 10.1016/S0140‐6736(22)00147‐7
– ident: e_1_2_12_72_1
  doi: 10.1016/j.ccell.2022.05.007
– ident: e_1_2_12_90_1
– ident: e_1_2_12_82_1
– ident: e_1_2_12_12_1
  doi: 10.1111/bjh.16956
– ident: e_1_2_12_59_1
  doi: 10.1016/j.ccell.2021.12.013
– ident: e_1_2_12_71_1
– ident: e_1_2_12_45_1
  doi: 10.1016/j.ejca.2022.01.035
– ident: e_1_2_12_26_1
  doi: 10.1016/S1473‐3099(21)00762‐3
– ident: e_1_2_12_34_1
  doi: 10.1056/NEJMoa2116044
– ident: e_1_2_12_4_1
  doi: 10.1016/S1470‐2045(20)30096‐6
SSID ssj0009908
Score 2.4069169
SecondaryResourceType review_article
Snippet Patients with hematologic malignancies can be immunocompromized because of their disease, anti‐cancer therapy, and concomitant immunosuppressive treatment....
Patients with hematologic malignancies can be immunocompromized because of their disease, anti-cancer therapy, and concomitant immunosuppressive treatment....
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3
SubjectTerms Antibodies, Monoclonal
Antiretroviral drugs
antiviral
Antiviral agents
Antiviral Agents - therapeutic use
Antiviral drugs
Blood cancer
Comorbidity
Coronaviruses
COVID-19
COVID-19 Vaccines
Health services
Humans
Immune response
Immune system
Immunization
Immunization (passive)
immunosuppression
Immunosuppressive agents
Infections
Lymphoma
Lymphoma - drug therapy
Malignancy
Monoclonal antibodies
monoclonal antibody
Narratives
Pandemics
Patients
Prophylaxis
Respiratory diseases
Review
Ritonavir
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Viral diseases
Title Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhon.3086
https://www.ncbi.nlm.nih.gov/pubmed/36251481
https://www.proquest.com/docview/2771243367
https://www.proquest.com/docview/2725441838
https://pubmed.ncbi.nlm.nih.gov/PMC9874581
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwEB4VDhUX-g8LFBmpak-Bje2Nk94QFG0rsVRVQUgcIjuxBSpkEbt7oCcegWfskzATO9luoRJCihRFmWSSeGb82Rl_A_ChWxAosN1I8cJFkutelJW2jLg0Gu05cVrR2uH9QdI_lN-Oe8chq5LWwnh-iHbCjTyjjtfk4NqMtqakoafYSgIBOYbfWCREm7_7Y8ochUG2DsKcCGQRNTS8s12-1Vw42xPdg5f3syT_Rq9197P3Ak6aB_dZJ782J2OzWfz-h9PxaW_2EhYDKmXb3oxewTNbvYbn--G_-xsYT7Nk2NCxQMY6YjSLy86v0SKGF5rpqmQ7B0dfd__c3MbZZzbQV55XnPkFMrWADWVMUYZ60JKFdVqongbnF6jDl3kavYXDvS8_d_pRqNcQFVKkSZRlDtFXIUsXO6mNy4o0EcKpEiGMcbg5xIciVSqVlhvXMz2hFSKqpFRaxFKJdzBfDSu7DMxRUSBXujSj8aPmWdrV1miD4YjjsevAp6bt8iKQmVNNjfPc0zDzHD9iTh-xAxut5KUn8HhAZq1p_jy48CjnSqEuIRKFt2hPo_PRHxVd2eGEZIjhDaNi2oElby2tEkQGCEbTuANqxo5aASL2nj1TnZ3WBN8Z1SCgKz_WZvLf5877BwParzxWcBUWOHqDzzpfg_nx1cS-R1A1Nuswx-X39dqJ7gD77SNU
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwEB7xkIALKs8uhdZIqD1F7NreOG5PFRQthV04AOIWOYmtrQRZtI9Db_0J_EZ-SWfiJMsKkJAiRZHHmShjez4_5huAg2ZKoMA2A8VTF0hu2oHObBZwmRhsz6EzimKHu72wcy1_37Zv5-BHFQvj-SHqBTfqGcV4TR2cFqQPp6yhfTSTQEQ-D4syxJkL0TrLyynjri7S0dHOWoCOiVfMs01-WNWc9UUvAObLc5LP8WvhgE4-wGqJHNlPb-o1mLP5Oix1y73xDRhPT7KwgWMlYeqI0Uoru_uLVhvcG2byjB1d3JweP_17bOnvrGeGnvub-SCWQsCWqUZRhrxcxspYKlRPE-h71OFTMY024frk19VRJyhzKgSpFFEYaO0QIaUycy0nTeJ0GoVCOJUhzEgcXg4xnIiUiqTliWsnbWEUop4wU0a0pBJbsJAPcvsRmKPEPS5zkaY5nuE6ahqbmASHDI7PrgHfqr8bpyXhOOW9uIs9VTKP0Q4x2aEB-7XkgyfZeEVmtzJQXHazUcyVQl1ChApfURdjB6FdD5PbwYRkiIUNR66oAdvenrUS9N4IGKNWA9SMpWsBIt-eLcn_9AsSbk15Aqjm16JNvPndceeiR_ed9wp-geXOVfc8Pj_tnX2CFUpv70-J78LCeDixewiCxsnnorH_Bx5XBgk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fT9swED8NJiFeJvYH6GCbJ03jKaK13Tje2wSryjYKD4B4i5zYVpEgrdrywBsfgc_IJ9ld7KarYNKkSFHkcy7KnX0___sdwJd2SaDAtRPFS59IbrqJts4mXBYG_Tn1RtHZ4eNB2j-XPy-7l3FXJZ2FCfwQzYQbtYy6v6YGPrZ-f0EaOkQrCQTkK_BSotuRd3N5uiDc1XU2OlpYSzAu8TnxbJvvz2suh6In-PLpNsm_4Wsdf3ob8CoCR_Y9WPo1vHDVG1g7jkvjb2G22MjCRp5FvtQpo4lWdn2HRhvdGGYqyw5OLo4OH-8fOvobG5hJoP5m4QxLLeBiplGUoSBnWTxKhepp_HyDOkImpuk7OO_9ODvoJzGlQlJKkaWJ1h4BUimt73hpCq_LLBXCK4soo_B4eYRwIlMqk44Xvlt0hVEIelKrjOhIJTZhtRpVbhuYp7w93vpM0xDPcJ21jStMgT0Gx2ffgr35383LyDdOaS-u88CUzHO0Q052aMHnRnIcODaekdmdGyiPrWyac6VQlxCpwlc0xdg-aNHDVG50SzJEwoYdV9aCrWDPRgkGb8SLWacFasnSjQBxby-XVFfDmoNbU5oAqvm19ol_fnfePxnQ_f3_Cn6CtdPDXv77aPBrB9YpuX3YI74Lq7PJrfuAEGhWfKx9_Q-0HwVE
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Management+of+patients+with+lymphoma+and+COVID-19%3A+Narrative+review+and+evidence-based+practical+recommendations&rft.jtitle=Hematological+oncology&rft.au=Passamonti%2C+Francesco&rft.au=Nicastri%2C+Emanuele&rft.au=Di+Rocco%2C+Alice&rft.au=Guarini%2C+Attilio&rft.date=2023-02-01&rft.eissn=1099-1069&rft.volume=41&rft.issue=1&rft.spage=3&rft_id=info:doi/10.1002%2Fhon.3086&rft_id=info%3Apmid%2F36251481&rft.externalDocID=36251481
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0278-0232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0278-0232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0278-0232&client=summon